ClinicalTrials.Veeva

Menu

Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD (M2W)

5

5 Santé

Status

Completed

Conditions

COPD

Study type

Observational

Funder types

Other

Identifiers

NCT02080936
FVIE_M2W

Details and patient eligibility

About

Peripheral muscle mass and strength are relevant indicators of COPD survival. Current guidelines recommend to assess muscle strength only in muscle wasted patients. However, a recent study reported quadriceps weakness without muscle wasting (Menon, M et al. Resp. Res.2012, 13:119). Thus, these guidelines raise the risk to miss out some weak patients. In clinical settings, fat-free-mass index (FFMI) is indicated as a simple index to assess muscle wasting. We aimed at determining the prevalence of patients entering in pulmonary rehabilitation (PR) a priori not eligible for muscle strength evaluation given the lack of muscle wasting clinical signs.

Enrollment

138 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who have got FFMI (bioimpedance)
  • Patients who have done quadriceps muscle strenght evaluation

Exclusion criteria

  • Patients without FFMI
  • Patients without quadriceps muscle strenght

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems